kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics
kyron.bio, a biotech company specializing in precision glycoengineering, announced a strategic partnership with Servier on March 9, 2026.
Under the agreement, kyron.bio will glycoengineer a Servier-selected antibody for a specific N-glycoform, with Servier funding the research and holding an option for further development.
Financial details are undisclosed.
The partnership builds on kyron.bio's 2024 Servier Golden Ticket award.
kyron.bio's platform enables precise control of glycan structures to improve antibody efficacy, safety, and scalability, achieving over 97% consistency.
kyron.bio raised €5.5M in seed funding in 2025 and is based at Paris Biotech Santé.